Limits...
Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer.

Zhang K, Zhou B, Zhang P, Zhang Z, Chen P, Pu Y, Song Y, Zhang L - Croat. Med. J. (2014)

Bottom Line: Nampt concentration in serum was measured by commercial ELISA kits for human Nampt.Serum Nampt level was an independent prognostic marker of non-muscle-invasive BC, with a higher serum Nampt level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio=2.85, 95% confidence interval, 1.01-8.06; P=0.048).Our results suggest that serum Nampt level may serve as a biomarker of BC and an independent prognostic marker of non-muscle-invasive BC.

View Article: PubMed Central - PubMed

Affiliation: Lin Zhang, Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, PR China, zhanglin@scu.edu.cn.

ABSTRACT

Aim: To analyze the serum nicotinamide phosphoribosyltransferase (Nampt) level and its prognostic value in bladder cancer (BC).

Methods: The study included 131 patients with transitional cell BC and 109 healthy controls from the West China Hospital of Sichuan University in the period between 2007 and 2013. Nampt concentration in serum was measured by commercial ELISA kits for human Nampt.

Results: The serum Nampt protein level in patients with BC (mean ± standard deviation, 16.02 ± 7.95 ng/mL) was significantly higher than in the control group (6.46 ± 2.08 ng/mL) (P < 0.001). Serum Nampt level was an independent prognostic marker of non-muscle-invasive BC, with a higher serum Nampt level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio=2.85, 95% confidence interval, 1.01-8.06; P=0.048).

Conclusion: Our results suggest that serum Nampt level may serve as a biomarker of BC and an independent prognostic marker of non-muscle-invasive BC.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier recurrence-free survival curves for non-muscle-invasive bladder cancer patients based on serum nicotinamide phosphoribosyltransferase (Nampt) level.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4228298&req=5

Figure 3: Kaplan-Meier recurrence-free survival curves for non-muscle-invasive bladder cancer patients based on serum nicotinamide phosphoribosyltransferase (Nampt) level.

Mentions: Cox multivariable regression analysis showed that serum Nampt level was an independent prognostic marker of non-muscle-invasive BC, with higher level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio = 2.85, 95% confidence interval = 1.01-8.06, P = 0.048) (Table 3). However, there was no significant association of serum Nampt level with RFS or OS in total BC patients and muscle-invasive BC patients (Figure 3).


Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer.

Zhang K, Zhou B, Zhang P, Zhang Z, Chen P, Pu Y, Song Y, Zhang L - Croat. Med. J. (2014)

Kaplan-Meier recurrence-free survival curves for non-muscle-invasive bladder cancer patients based on serum nicotinamide phosphoribosyltransferase (Nampt) level.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4228298&req=5

Figure 3: Kaplan-Meier recurrence-free survival curves for non-muscle-invasive bladder cancer patients based on serum nicotinamide phosphoribosyltransferase (Nampt) level.
Mentions: Cox multivariable regression analysis showed that serum Nampt level was an independent prognostic marker of non-muscle-invasive BC, with higher level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio = 2.85, 95% confidence interval = 1.01-8.06, P = 0.048) (Table 3). However, there was no significant association of serum Nampt level with RFS or OS in total BC patients and muscle-invasive BC patients (Figure 3).

Bottom Line: Nampt concentration in serum was measured by commercial ELISA kits for human Nampt.Serum Nampt level was an independent prognostic marker of non-muscle-invasive BC, with a higher serum Nampt level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio=2.85, 95% confidence interval, 1.01-8.06; P=0.048).Our results suggest that serum Nampt level may serve as a biomarker of BC and an independent prognostic marker of non-muscle-invasive BC.

View Article: PubMed Central - PubMed

Affiliation: Lin Zhang, Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, PR China, zhanglin@scu.edu.cn.

ABSTRACT

Aim: To analyze the serum nicotinamide phosphoribosyltransferase (Nampt) level and its prognostic value in bladder cancer (BC).

Methods: The study included 131 patients with transitional cell BC and 109 healthy controls from the West China Hospital of Sichuan University in the period between 2007 and 2013. Nampt concentration in serum was measured by commercial ELISA kits for human Nampt.

Results: The serum Nampt protein level in patients with BC (mean ± standard deviation, 16.02 ± 7.95 ng/mL) was significantly higher than in the control group (6.46 ± 2.08 ng/mL) (P < 0.001). Serum Nampt level was an independent prognostic marker of non-muscle-invasive BC, with a higher serum Nampt level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio=2.85, 95% confidence interval, 1.01-8.06; P=0.048).

Conclusion: Our results suggest that serum Nampt level may serve as a biomarker of BC and an independent prognostic marker of non-muscle-invasive BC.

Show MeSH
Related in: MedlinePlus